Shanghai - Delayed Quote CNY

Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS)

32.96
-0.48
(-1.44%)
At close: 3:00:03 PM GMT+8
Loading Chart for 688513.SS
  • Previous Close 33.44
  • Open 33.50
  • Bid 32.93 x --
  • Ask 32.96 x --
  • Day's Range 32.81 - 33.60
  • 52 Week Range 28.11 - 46.84
  • Volume 1,955,339
  • Avg. Volume 3,516,345
  • Market Cap (intraday) 5.818B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 25.95
  • EPS (TTM) 1.27
  • Earnings Date --
  • Forward Dividend & Yield 0.58 (1.73%)
  • Ex-Dividend Date Jul 1, 2024
  • 1y Target Est --

Chengdu Easton Biopharmaceuticals Co., Ltd. engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms in anesthetic/analgesics, cardiovascular, oncology, pediatrics, and other therapeutic fields. It also offers active pharmaceutical ingredients in oncology, cardiovascular, anesthetic/analgesics, anti-inflammatory, gastrointestinal, antiemetic, neurology/psychiatry, and urinary system therapeutic categories. The company was founded in 2009 and is based in Chengdu, China.

www.eastonpharma.cn

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 688513.SS

View More

Performance Overview: 688513.SS

Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

688513.SS
9.39%
SSE Composite Index (000001.SS)
1.56%

1-Year Return

688513.SS
15.47%
SSE Composite Index (000001.SS)
8.21%

3-Year Return

688513.SS
0.81%
SSE Composite Index (000001.SS)
10.36%

5-Year Return

688513.SS
37.88%
SSE Composite Index (000001.SS)
18.59%

Compare To: 688513.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 688513.SS

View More

Valuation Measures

Annual
As of 5/13/2025
  • Market Cap

    5.90B

  • Enterprise Value

    4.55B

  • Trailing P/E

    26.33

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.39

  • Price/Book (mrq)

    2.14

  • Enterprise Value/Revenue

    3.40

  • Enterprise Value/EBITDA

    19.10

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    16.70%

  • Return on Assets (ttm)

    3.71%

  • Return on Equity (ttm)

    8.31%

  • Revenue (ttm)

    1.34B

  • Net Income Avi to Common (ttm)

    223.81M

  • Diluted EPS (ttm)

    1.27

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.49B

  • Total Debt/Equity (mrq)

    5.18%

  • Levered Free Cash Flow (ttm)

    15.83M

Research Analysis: 688513.SS

View More

Company Insights: 688513.SS

Research Reports: 688513.SS

View More

People Also Watch